Opinion|Videos|December 20, 2023
PSMA PET/CT Imaging Utility in Real-World Practices
Author(s)Jaideep S. Sohi, MD
Jaideep S. Sohi, MD, discusses how PSMA PET imaging has impacted diagnosis and management of prostate cancer in clinical practice, when and why it should be considered over conventional imaging, and which PSMA PET tracers are available.
Advertisement
Episodes in this series
Advertisement
Related to this article
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5